Market Research Report
Epiomic Epidemiology Series: Overactive Bladder Forecast in 12 Major Markets 2017-2027
|Published by||Black Swan Analysis||Product code||479875|
|Published||Content info||48 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Overactive Bladder Forecast in 12 Major Markets 2017-2027|
|Published: March 1, 2017||Content info: 48 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Overactive Bladder in 12 Major Markets
Overactive Bladder (OAB) is a (relatively) common, disabling condition associated with significant negative impact on quality of life, sleep and mental health. It is characterised as a sudden, strong uncontrollable urge to urinate.
This report provides the current prevalent population for Overactive Bladder across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Overactive Bladder have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Patients with OAB often also have other bladder-related symptoms such as:
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.